Cargando…

Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys

IMPORTANCE: The US Food and Drug Administration (FDA) created the exception from informed consent (EFIC) pathway in 1996 to allow some emergency trials to enroll patients without informed consent. To protect individual autonomy and preserve public trust, the FDA requires that EFIC trial investigator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feldman, William B., Hey, Spencer P., Franklin, Jessica M., Kesselheim, Aaron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659147/ https://www.ncbi.nlm.nih.gov/pubmed/31339546 http://dx.doi.org/10.1001/jamanetworkopen.2019.7591

Ejemplares similares

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Community consultation in the pediatric intensive care unit for an exception from informed consent Trial: A survey of patient caregivers
por: Ross, Catherine E., et al.
Publicado: (2023)

Community consultation for Exception from Informed consent (EFIC) before and during the COVID-19 pandemic
por: Gagnon, David J., et al.
Publicado: (2022)

Improving Community Understanding of Medical Research: Audience Response Technology for Community Consultation for Exception to Informed Consent
por: Vohra, Taher, et al.
Publicado: (2014)

Exception from informed consent trials: social-media-based community consultation campaigns are representative of target communities
por: Farley, Paige, et al.
Publicado: (2021)

A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes
por: Gyawali, Bishal, et al.
Publicado: (2018)

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2020)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Exceptions to the rule of informed consent for research with an intervention
por: Rebers, Susanne, et al.
Publicado: (2016)

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2019)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Public opinion of a stroke clinical trial using exception from informed consent
por: Goldstein, Joshua N., et al.
Publicado: (2010)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Informed consent and ethics committee approval in laboratory medicine
por: Borovecki, Ana, et al.
Publicado: (2018)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Exception from informed consent for biomedical research in emergency settings: A study from Jordan
por: Al-Shatnawi, Samah F., et al.
Publicado: (2021)

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
por: Kesselheim, Aaron S, et al.
Publicado: (2015)

Ethics Review Committee approval and informed consent: an analysis of biomedical publications originating from Sri Lanka
por: Sumathipala, Athula, et al.
Publicado: (2008)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Consultation, Consent, and the Silencing of Indigenous Communities
por: Townsend, Leo, et al.
Publicado: (2020)

Reporting ethics committee approval and informed consent: Review of an Ayurvedic journal
por: Bolshete, Pravin M.
Publicado: (2015)

Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study
por: Hwang, Thomas J, et al.
Publicado: (2016)

An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
por: Hey, Spencer Phillips, et al.
Publicado: (2016)

Exception from informed consent in the era of social media: The SEGA stroke trial experience
por: Inam, Mehmet Enes, et al.
Publicado: (2021)

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021)

Informed Consent in Pragmatic Trials: Results from a Survey of Trials published 2014–2019
por: Zhang, Jennifer Zhe, et al.
Publicado: (2021)

Outcomes of the 340B Drug Pricing Program: A Scoping Review
por: Knox, Ryan P., et al.
Publicado: (2023)

Assessment of Length and Readability of Informed Consent Documents for COVID-19 Vaccine Trials
por: Emanuel, Ezekiel J., et al.
Publicado: (2021)

Variability in the Perception of Informed Consent for IV-tPA during Telestroke Consultation
por: Thomas, Lisa, et al.
Publicado: (2012)

Getting the Right Evidence After Drug Approval
por: Vreman, Rick A., et al.
Publicado: (2020)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Patient and surrogate attitudes via an interviewer-administered survey on exception from informed consent enrollment in the Prehospital Air Medical Plasma (PAMPer) trial
por: Campwala, Insiyah, et al.
Publicado: (2020)

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Designing Dynamic Informed Consent For Public Health Research
por: Miranda, P, et al.
Publicado: (2023)

Large Language Model−Based Chatbot vs Surgeon-Generated Informed Consent Documentation for Common Procedures
por: Decker, Hannah, et al.
Publicado: (2023)

Changing FDA Approval Standards: Ethical Implications for Patient Consent
por: Darrow, Jonathan J., et al.
Publicado: (2021)

Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
por: Wang, Bo, et al.
Publicado: (2015)

Informed consent
por: Liew, J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sg7enkqgtaunahm60pf08f5pk1